Q1 2026 Danaher Corp Earnings Call Transcript
Key Points
- Danaher Corp (DHR) reported better-than-expected adjusted EPS growth, driven by strong execution and productivity gains.
- The company saw continued strength in bioprocessing and life sciences, which largely offset the impact of a lighter-than-normal Q1 respiratory season.
- Geographically, there was an acceleration in life sciences and biotechnology businesses in China, with mid-single-digit growth.
- Danaher Corp (DHR) announced the pending acquisition of Masimo, expected to be accretive to adjusted diluted net earnings per share in the first full year post-acquisition.
- The company generated $1.1 billion of free cash flow in the quarter, resulting in a free cash flow to net income conversion ratio of 105%.
- Core revenue in developed markets was down slightly, with a mid-single-digit decline in North America.
- The diagnostics segment saw a core revenue decline of 4%, impacted by pricing headwinds in China due to volume-based procurement and reimbursement policies.
- Cepheid's revenue declined in the quarter as respiratory revenue was down approximately 25% year-over-year.
- Life sciences instruments businesses experienced a low single-digit decline, primarily driven by weakness in North America academic research customers.
- The global environment remains dynamic, with potential pressures from ongoing conflicts, such as in the Middle East, which could impact future performance.
My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's first-quarter 2026 earnings results conference call. (Operator Instructions)
I will now turn the call over to Ms. Rachel Vatnsdal, Vice President of Investor Relations. Ms. Vatnsdal, you may begin your conference.
Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; and Matt Gugino, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, quarterly report on Form 10-Q, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call.
And a note containing details of historical and anticipated future financial performance are all available on the Investors section of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
